Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

PLoS ONE - United States
doi 10.1371/journal.pone.0133968
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Clinical Experience With Fixed Bimonthly Aflibercept Dosing in Treatment-Experienced Patients With Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Ophthalmology
2015English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration

European Ophthalmic Review
2012English

Clinical Risk Factors for Poor Anatomic Response to Ranibizumab in Neovascular Age-Related Macular Degeneration§

Open Ophthalmology Journal
Ophthalmology
2014English

Retinal Metabolic and Structural Alterations in Response to Aflibercept Treatment in Neovascular Age‐related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2018English

Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

JAMA Ophthalmology
Ophthalmology
2016English

Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data From an Observational Study

Ophthalmology
Ophthalmology
2016English

Worsening Anatomic Outcomes Following Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Well Controlled With Ranibizumab [Corrigendum]

Clinical Ophthalmology
Ophthalmology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy